ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic(R) technology has been licensed by Ginkgo ...

ProteoNic BV, a leading provider of premium vector technology for biopharmaceutical and viral vector production, today announced that its proprietary 2G UNic® technology has been licensed by Ginkgo ...

Integrated analytical workflows are transforming cell line development by combining faster screening and streamlined decision-making.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the establishment of its rare kidney ...

Diabetes goes beyond just glucose control, and recent advancements in research are enhancing drug development for the disease.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

A new artificial intelligence model could help design antibodies that better protect the body against viruses and disease.

The PrIMAVeRa project develops a platform to evaluate how mAbs can combat AMR by reducing antibiotic use and providing ...

Since its introduction in the late 1980s, HIV antiretroviral therapy (ART) has saved millions of lives by transforming HIV from a fatal disease into a chronic, manageable condition. Despite these ...

CAR T-cell therapies achieve high response rates in relapsed/refractory MCL but have severe toxicities and complex manufacturing processes. Bispecific antibodies offer logistical advantages and ...

Researchers recently enhanced the titer of a cell line still in development to produce adenovirus viral vectors by 7.5-fold, and without the risk of also producing replication-competent adenoviruses ...